Market Overview
Global Enzyme Linked Immunosorbent Assay Market reached US$ 2.14 billion in 2023 and is expected to reach US$ 3.35 billion by 2031, growing at a CAGR of 5.8% during the forecast period 2024-2031.
Enzyme-linked Immunosorbent Assay is useful for detecting and estimating hormone levels such as human chorionic gonadotropin (HCG), follicle-stimulating hormone (FSH), and testosterone, as well as tracking disease outbreaks in communities such as chlamydia or influenza (the flu), and screening blood donations for possible viral components such as HIV. It detects nonmedical drug usage, such as the presence of amphetamines and cocaine in the body.
Rising infectious diseases globally are expected to drive the demand for enzyme-linked immunosorbent assay tests due to their specificity and identification of the antibodies. For instance, according to the World Health Organization's (WHO) 2024 Global Hepatitis Report, the number of deaths from viral hepatitis is rising. The disease is the second leading infectious cause of death in the world, accounting for 1.3 million deaths annually.
Executive Summary
Market Scope
Metrics | Details |
CAGR | XX% |
Market Size Available for Years | 2022-2031 |
Estimation Forecast Period | 2024-2031 |
Revenue Units | Value (US$ Mn) |
Segments Covered | Test Type, Product, Application, End-user |
Regions Covered | North America, Europe, Asia-Pacific, South America, and Middle East & Africa |
Largest Region | North America |
Fastest Growing Region | Asia-Pacific |
Report Insights Covered | Competitive Landscape Analysis, Company Profile Analysis, Market Size, Share, Growth, Demand, Recent Developments, Mergers and Acquisitions, New Product Launches, Growth Strategies, Revenue Analysis, Porter’s Analysis, Pricing Analysis, Regulatory Analysis, Supply-Chain Analysis and Other key Insights. |
For more details on this report – Request for Sample
Market Dynamics: Drivers & Restraints
Increasing incidence of infectious diseases
The rising incidence of infectious diseases is expected to drive the enzyme-linked immunosorbent assay market growth. With the rising number of infectious diseases, there is a growing demand for enzyme-linked immunosorbent assay tests in laboratories. Antibodies against several infectious diseases such as Lyme disease, brucellosis, syphilis HIV and hepatitis among others can be detected and measured using ELISA.
Enzyme-linked immunosorbent assay is one of the most widely used diagnostic procedures for identifying antibodies, antigens, and other biomarkers linked to infectious illnesses. With the rising number of infectious diseases, government organizations, diagnostic centers and other laboratories depend on enzyme-linked immunosorbent assay for detecting the antibodies. There is a growing number of infectious diseases globally.
For instance, in 2022, the CDC received reports of about 63,000 cases of Lyme disease from state health agencies and the District of Columbia. This figure reflects cases recorded during routine national surveillance, which is simply one method used by public health professionals to track diseases. According to recent predictions utilizing alternative approaches, approximately 476,000 people in the United States will be identified and treated for Lyme disease each year. This number is likely to include patients treated based on clinical suspicion but do not have Lyme disease.
These infectious diseases, along with other diseases, require the utilization of enzyme-linked immunosorbent assay kits to detect antibodies and biomarkers. Thus, the increasing incidence of infectious diseases is expected to drive the Enzyme-Linked Immunosorbent Assay market growth.
Threat of substitution from alternative technologies
The chance of substitution from other technologies is a key obstacle to the growth and adoption of the ELISA (Enzyme-Linked Immunosorbent Assay) market. As innovative diagnostic and research technologies emerge, they provide benefits such as increased sensitivity, faster findings, and lower costs, potentially replacing or reducing the necessity for traditional ELISA assays. Thus, the above factors could hinder the enzyme-linked immunosorbent assay market
Market Segment Analysis
The global enzyme-linked immunosorbent assay market is segmented based on test type, product, application, end-user and region.
Sandwich ELISA segment is expected to dominate the enzyme-linked immunosorbent assay market share
The sandwich ELISA segment is expected to hold a major portion of the enzyme-linked immunosorbent assay market share. Sandwich ELISAs are the most common type of ELISA. The antigen is sandwiched between two specific antibodies, often known as matched antibody pairs. A microplate is covered with a capture antibody, a sample is added, and the protein of interest adheres to the plate and becomes immobilized.
A sandwich ELISA is more sensitive and robust because the antibody binds to two different sites on the antigen. This improves the binding selectivity of both the primary capture and detection antibodies to the antigen. The sandwich ELISA format is widely utilized due to its sensitivity and specificity.
New sandwich ELISA kits are being introduced into the market by several players which could contribute to the segment’s expansion. An increasing number of product launches could help drive the segment’s growth. For instance, in June 2024, ArcticZymes Technologies launched its SAN HQ 2.0 ELISA kit. This traditional sandwich ELISA is designed to detect and quantify the SAN HQ 2.0 enzyme in samples taken from the manufacturing stages of a complicated biomanufacturing process, such as the creation of viral vectors.
Thus, the sandwich ELISA segment is expected to hold the major portion of the enzyme-linked immunosorbent assay market share with the increasing innovation of new sandwich ELISA kits and their effectiveness in finding antibodies over other types of tests.
Market Geographical Share
North America is expected to hold a significant position in the enzyme-linked immunosorbent assay market share
North America is expected to hold a dominant position in the enzyme-linked immunosorbent assay market share owing to the increasing innovation of technological products, increasing research and development, the presence of a large number of key market players, and the rising incidence of infectious diseases. The region has highly equipped laboratories and it will invest more in the R&D department.
Several key players introduce a wide range of enzyme-linked immunosorbent assay products and kits with advanced features which could expand the region’s market expansion. For instance, on February 13, 2023, Charles River Laboratories International, Inc. launched its first Enzyme-Linked Immunosorbent Assay (ELISA) Kit for the detection and quantitation of residual host cell proteins (HCP) in CHO-based biotherapeutics.
Similarly, on May 24, 2022, Molecular Devices, LLC. unveiled five ready-made workcells for enzyme-linked immunosorbent assay (ELISA) workflows, with automation capabilities ranging from entry-level to advanced. Automation of labor-intensive plate-based assays improves walkaway time, throughput, and reproducibility by lowering the number of common, repetitive, hands-on steps for researchers.
The introduction of advanced instruments and systems will increase the adoption of these enzyme-linked immunosorbent assay products by several laboratories, diagnostic centers and research institutes, which will increase the demand for the products and expand of region’s market as well. Several market players in the region invest huge resources in innovating enzyme-linked immunosorbent assay products. Thus, the above factors are expected to drive the region’s market growth.
Market Segmentation
By Test Type
- Direct ELISA
- Indirect ELISA
- Sandwich ELISA
- Competitive ELISA
By Product
- Kits & Reagents
- ELISA Analyzers
- Automated
- Semi-automated
By Application
- Drug Discovery
- Infectious Diseases
- Cancer Detection
- Protein Quantification
- Others
By End-user
- Hospitals
- Academic and Research Institutes
- Pharmaceutical & Biotechnology Companies
- Diagnostic Laboratories
- Others
By Region
- North America
- The U.S.
- Canada
- Mexico
- Europe
- Germany
- UK
- France
- Italy
- Spain
- Rest of Europe
- South America
- Brazil
- Argentina
- Rest of South America
- Asia-Pacific
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
- Middle East and Africa
Competitive Landscape
The major global players in the market include Thermo Fisher Scientific, Inc., American Laboratory Products Company (ALPCO), ZEUS Scientific, Inc., Life Technologies Corporation, Bio-Rad Laboratories, Inc., QuidelOrtho Corporation, Biomerieux S.A., Gemelli Biotech, BD and Enzo Biochem Inc. among others.
Why Purchase the Report?
- To visualize the global enzyme-linked immunosorbent assay market segmentation based on test type, product, application, end-user, and region as well as understand key commercial assets and players.
- Identify commercial opportunities by analyzing trends and co-development.
- Excel data sheet with numerous data points of enzyme-linked immunosorbent assay market-level with all segments.
- PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
- Product mapping available as Excel consisting of key products of all the major players.
The global enzyme-linked immunosorbent assay market report would provide approximately 53 tables, 47 figures, and 176 pages.
Target Audience 2024
- Manufacturers/ Buyers
- Industry Investors/Investment Bankers
- Research Professionals
- Emerging Companies
